Trial Profile
Long-term IOP-lowering efficacy and safety of bimatoprost 0.01% for the treatment of open angle glaucoma: A cross-sectional study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jan 2020
Price :
$35
*
At a glance
- Drugs Bimatoprost (Primary)
- Indications Low tension glaucoma; Open-angle glaucoma
- Focus Therapeutic Use
- 14 Jan 2020 Status changed from not yet recruiting to completed.
- 15 Dec 2017 New trial record